MedTrace Logo

The Effect of Brimonidine

NCT03959176 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-02-01

Study results available
· View outcomes & findings →

Summary

This study will evaluate whether pre-treating patients with Brimonidine 0.2% before and/or after dilating the pupils will help to control the changes in intraocular pressure often seen when using dilating drops. The study will also evaluate the effects of different sequences of administering dilating drops along with Brimonidine on pupil size and reactivity.

Conditions

  • Intraocular Pressure

Interventions

DRUG

Brimonidine

2 drops administered once in the left eye in both study arms

DRUG

Tropicamide

1 drop administered at two different times points in both eyes in both study arms

DRUG

Phenylephrine Ophthalmic Product

1 drop administered at two different time points in both eyes in both study arms

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Keith Walter, MD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-20
Primary Completion
2019-07-20
Completion
2019-07-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03959176 on ClinicalTrials.gov